Last reviewed · How we verify
Prospective TDM Arm
This is a prospective therapeutic drug monitoring (TDM) study arm, not a drug itself, designed to optimize dosing through real-time concentration monitoring.
At a glance
| Generic name | Prospective TDM Arm |
|---|---|
| Also known as | VFEND |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
The 'Prospective TDM Arm' refers to a clinical trial cohort at Johns Hopkins University that uses therapeutic drug monitoring to guide individualized drug dosing in real-time, rather than using fixed standard doses. This approach aims to maintain drug concentrations within optimal therapeutic windows, potentially improving efficacy and reducing toxicity compared to standard dosing.
Approved indications
Common side effects
Key clinical trials
- Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin (NA)
- A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |